Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Core Insights - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases [3][4] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1][2] Company Overview - Ventyx specializes in medicinal chemistry, structural biology, and immunology to discover differentiated oral small molecule therapeutics for conditions with high unmet medical needs [3] - The company has extensive experience in clinical development, facilitating the rapid progression of drug candidates through clinical trials [3] Product Pipeline - Ventyx's portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that has completed Phase 2 studies for obesity-related cardiovascular risk factors and Parkinson's disease [4] - The inflammatory bowel disease portfolio features two Phase 2 compounds: tamuzimod (VTX002), a S1P1R modulator, and VTX958, a TYK2 inhibitor [4]